Cantor Fitzgerald Brokers Reduce Earnings Estimates for PTCT

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Cantor Fitzgerald cut their FY2026 EPS estimates for shares of PTC Therapeutics in a report released on Wednesday, August 20th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings per share of ($6.71) for the year, down from their previous forecast of ($6.57). Cantor Fitzgerald has a “Overweight” rating and a $120.00 price target on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.24. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The firm had revenue of $178.88 million during the quarter, compared to the consensus estimate of $173.01 million. During the same period last year, the firm posted ($1.29) EPS. The firm’s quarterly revenue was down 4.2% on a year-over-year basis. PTC Therapeutics has set its FY 2025 guidance at EPS.

PTCT has been the subject of several other research reports. Wall Street Zen cut shares of PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, August 9th. Wells Fargo & Company lowered their price objective on shares of PTC Therapeutics from $79.00 to $73.00 and set an “overweight” rating for the company in a research report on Wednesday. JPMorgan Chase & Co. lowered their price objective on shares of PTC Therapeutics from $75.00 to $67.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. UBS Group raised their price objective on shares of PTC Therapeutics from $71.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, July 29th. Finally, Cowen restated a “hold” rating on shares of PTC Therapeutics in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $69.15.

PTC Therapeutics Trading Up 3.4%

PTCT opened at $50.57 on Friday. The stock has a market capitalization of $4.02 billion, a PE ratio of 7.26 and a beta of 0.54. PTC Therapeutics has a 1-year low of $30.41 and a 1-year high of $58.38. The firm has a 50-day moving average price of $48.86 and a two-hundred day moving average price of $49.04.

Insider Activity at PTC Therapeutics

In other news, CFO Pierre Gravier sold 2,516 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $49.46, for a total transaction of $124,441.36. Following the completion of the sale, the chief financial officer owned 71,920 shares in the company, valued at $3,557,163.20. The trade was a 3.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Matthew B. Klein sold 10,739 shares of the business’s stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $51.74, for a total transaction of $555,635.86. Following the transaction, the chief executive officer owned 337,767 shares of the company’s stock, valued at approximately $17,476,064.58. This represents a 3.08% decrease in their position. The disclosure for this sale can be found here. 5.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new position in PTC Therapeutics during the second quarter valued at approximately $453,000. CANADA LIFE ASSURANCE Co grew its holdings in PTC Therapeutics by 8.8% during the second quarter. CANADA LIFE ASSURANCE Co now owns 21,793 shares of the biopharmaceutical company’s stock valued at $1,065,000 after purchasing an additional 1,755 shares during the period. Tower Research Capital LLC TRC grew its holdings in PTC Therapeutics by 331.5% during the second quarter. Tower Research Capital LLC TRC now owns 7,309 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 5,615 shares during the period. LGL Partners LLC grew its holdings in PTC Therapeutics by 33.3% during the second quarter. LGL Partners LLC now owns 16,000 shares of the biopharmaceutical company’s stock valued at $806,000 after purchasing an additional 4,000 shares during the period. Finally, E Fund Management Co. Ltd. grew its holdings in PTC Therapeutics by 104.3% during the second quarter. E Fund Management Co. Ltd. now owns 10,898 shares of the biopharmaceutical company’s stock valued at $532,000 after purchasing an additional 5,564 shares during the period.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.